Key clinical point: Ipriflavone significantly increases bone mineral density (BMD) in postmenopausal women with osteoporosis.
Major finding: In a random-effects model, patients receiving ipriflavone had a greater improvement in BMD of the lumbar spine compared with those receiving placebo (standardized mean difference, 0.35; P = .009). Adverse drug withdrawal events were comparable between groups.
Study details: A meta-analysis of 11 randomized control trials including 1,605 patients.
Disclosures: This study was supported by the Natural Science Foundation of China, Sichuan Project, Sichuan University Project, and Shenzhen Projects. The authors declared no conflicts of interest.
Hu Q et al. Pharmacol Res. 2020 May 12. doi: 10.1016/j.phrs.2020.104860